Brief: Autolus Therapeutics Submits Biologics License Application To U.S. Food And Drug Administration
27/11/2023 12:14
Nov 27 (Reuters) - Autolus Therapeutics PLC AUTL.O :
* AUTOLUS THERAPEUTICS SUBMITS BIOLOGICS LICENSE APPLICATION
TO
U.S. FOOD AND DRUG ADMINISTRATION FOR OBECABTAGENE AUTOLEUCEL
(OBE-CEL) FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) ADULT
B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
* AUTOLUS THERAPEUTICS- PLANS TO SUBMIT MARKETING
AUTHORIZATION
APPLICATION FOR OBE-CEL IN RELAPSED/REFRACTORY ALL TO EMA IN
FIRST HALF OF 2024
Source text for Eikon: ID:nGNXbTb2wP
Further company coverage: AUTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants